← FDA DRUG APPROVALS

FDA ANDA · ANDA202220

PROTRIPTYLINE HYDROCHLORIDE

Sponsor: EPIC PHARMA LLC

APPLICATION
ANDA202220
TYPE
ANDA
ORIGINAL APPROVAL
2012-11-19
LATEST ACTION
2026-01-07
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

PROTRIPTYLINE HYDROCHLORIDEPrescription
PROTRIPTYLINE HYDROCHLORIDE 10MG · TABLET · ORAL
PROTRIPTYLINE HYDROCHLORIDEPrescription
PROTRIPTYLINE HYDROCHLORIDE 5MG · TABLET · ORAL

Approval history

2026-01-07Labeling · Supplement 4 · standardAP
2020-08-11Manufacturing (CMC) · Supplement 3AP
2014-07-17Labeling · Supplement 1 · standardAP
2012-11-19OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →